Second allogeneic transplantation in relapsed acute leukemia - a risk worth taking?

ABSTRACT: Second allogeneic stem cell transplantation (SCT2) presents a potentially curative treatment approach in patients who relapsed after first allogeneic transplant procedure. Currently there is no consensus on second allografting. The aim of our study was to analyze the outcome and prognostic factors of SCT2 in relapsed acute leukemia setting. The study comprised 60 patients at a median age of 44.7 years (37 females, 23 males) who underwent SCT2 due to relapsed acute leukemia between 2000 and 2024 in our center. Median remission duration after SCT1 was 13.6 (IQR 30.1) months and median time from relapse to SCT2 was 4 (IQR 3) months. Disease-risk index at SCT2 was as follows: low - 2 (3.3%), intermediate - 29 (48,4%), high - 27 (45%) and very high - 2 (3.3%). The same donor was used in 52 proc

SUBMITTER: Zielinska P 

PROVIDER: S-EPMC12432055 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature